Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.
Richard FurieEric F MorandAnca D AskanaseEdward M VitalJoan T MerrillRubana N KalyaniGabriel AbreuLilia PinedaRaj TummalaPublished in: Lupus (2021)
Analyses of pooled TULIP-1 and TULIP-2 data support that anifrolumab reduces flares while permitting glucocorticoid taper in patients with SLE.ClinicalTrials.gov identifiersTULIP-1 NCT02446912 (clinicaltrials.gov/ct2/show/NCT02446912);TULIP-2 NCT02446899 (clinicaltrials.gov/ct2/show/NCT02446899).